Fig. 11From: Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapsesEvaluation results based on the utility modelling for patients starting at EDSS 5. This display is analogous to that in Fig. 10, albeit based on a scenario that considers more severe relapsesBack to article page